Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $225.6 million.

  • Axsome Therapeutics' Accounts Payables rose 8467.78% to $225.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 8467.78%. This contributed to the annual value of $148.0 million for FY2024, which is 6351.97% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Accounts Payables of $225.6 million as of Q3 2025, which was up 8467.78% from $170.9 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Accounts Payables registered a high of $225.6 million during Q3 2025, and its lowest value of $12.6 million during Q1 2022.
  • Over the past 4 years, Axsome Therapeutics' median Accounts Payables value was $82.7 million (recorded in 2024), while the average stood at $95.5 million.
  • In the last 5 years, Axsome Therapeutics' Accounts Payables skyrocketed by 36664.13% in 2023 and then soared by 4073.57% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Accounts Payables stood at $51.6 million in 2022, then soared by 75.28% to $90.5 million in 2023, then soared by 63.52% to $148.0 million in 2024, then skyrocketed by 52.47% to $225.6 million in 2025.
  • Its Accounts Payables was $225.6 million in Q3 2025, compared to $170.9 million in Q2 2025 and $149.2 million in Q1 2025.